The potential public health impact of Herpes Zoster vaccination in the 65 years of age cohort in Italy

The potential public health impact of Herpes Zoster vaccination in the 65 years of age cohort in Italy

Herpes Zoster (HZ) presents a considerable public health burden in Italy among people aged ≥50 years. This study aimed to assess the clinical and economic impact of HZ vaccination in the 65 years of age (YOA) cohort in Italy, by comparing the new Adjuvanted Recombinant Zoster Vaccine (RZV) with the...

Full description

Bibliographic Details
Main Authors: Antonio Volpi, Sara Boccalini, Silvia Dari, Christopher Clarke, Desmond Curran, Idalba Loiacono, Andrea Pitrelli, Anna Puggina, Roberta Tosatto, Desirée Van Oorschot, Elisabetta Franco
Format: Article
Language:English
Published: Taylor & Francis Group 2020-02-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
herpes zoster
vaccination
public health impact
adjuvanted vaccine
live-attenuated vaccine
Online Access:http://dx.doi.org/10.1080/21645515.2019.1657753

Similar Items

Similar Items